Abomics’ pharmacogenetic test panel seen increasingly useful in public health care

The matter was reported by Yle, Southwest Finland Regional News, on Friday 28.2.2020, https://yle.fi/uutiset/3-11231961. Jari Forsström, MD, specialist in internal medicine and medical director of Abomics, was interviewed on Yle’s TV broadcast, together with university expert, Assistant Professor Aleksi Tornio and patients who benefited from the test.

Based on strong scientific evidence, the B-Frama-D laboratory test is available with a doctor’s prescription in public health care and privately, e.g. in public health care. Through Synlab, Terveystalo and Mehiläinen.

Share article:

Abomics Strengthens Bioinformatics Expertise

Abomics has appointed Andrea Izquierdo Bouldstridge as Lead Bioinformatician. Andrea strengthens the company’s expertise in

New Appointment to Abomics’ Medical Team

Turku, Finland, 18. May 2025 The Abomics team has been strengthened with a new addition,

Abomics Announces Leadership and Team Appointments

Turku, Finland, May 23, 2025 – Abomics is pleased to share updates to its leadership

Abomicsin ja Multirecin fuusio voimaan vuoden 2025 alusta

Merger of Abomics and Multirec Effective from Early 2025

As of January 1, 2025, Abomics Oy and Multirec Oy have merged their operations. This union brings together the

Abomics’ Interpreted Pharmacogenetic Tests to Be Introduced in Ostrobothnia Health Centers – A Major Step Towards Personalized Medicine

Writer: Minna Pauliina Kataja -15.11.2024 Adverse drug reactions and determining correct dosages are still often

dna

Variants in the CYP1A2 Gene Affect the Safety of Clozapine

Abomics has long been the only pharmacogenetic test provider in Finland to include CYP1A2 gene